Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BeiGene, Ltd.
< Previous
1
2
Next >
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
July 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
July 18, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
June 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
May 24, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
May 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
May 08, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
April 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
April 24, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
April 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
March 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
March 07, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
March 06, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
February 29, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at Upcoming Investor Conferences
February 28, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
February 27, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
February 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
January 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
December 22, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
November 29, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
November 28, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
November 21, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
November 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
November 09, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the Jefferies London Healthcare Conference
November 08, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
October 20, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
October 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
October 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.